Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Saray Galván-Ruíz"'
Autor:
Marta Mori-De Santiago, María Jesús Blanco-Sánchez, David Aguiar-Bujanda, Salvador Saura-Grau, Jose E. Lorenzo-Barreto, María Hernández-Sosa, Saray Galván-Ruíz, Arancha Dueñas-Comino, Laura Ros-Sanjuan, Uriel Bohn-Sarmiento, Ana M. Vargas-Prado
Publikováno v:
Oncology Research and Treatment. 41:755-761
Background: A high neutrophil to lymphocyte ratio (NLR) has been associated with adverse outcomes in non-small cell lung cancer (NSCLC). However, information on epidermal growth factor receptor (EGFR)-mutant advanced NSCLC is scarce, and most of the
Autor:
David Aguiar-Bujanda, María Jesús Blanco-Sánchez, Salvador Saura-Grau, Uriel Bohn-Sarmiento, Saray Galván-Ruíz, María Hernández-Sosa, Samuel Hernández-Sarmiento
Publikováno v:
Clinical Lymphoma Myeloma and Leukemia. 15:761-765
Background Late-onset neutropenia (LON) is a known adverse effect to rituximab therapy. Information about its real incidence and clinical implications comes from case reports and few retrospective studies specifically designed to study LON. However,
Autor:
Samuel Hernández-Sarmiento, María Jesús Blanco-Sánchez, Uriel Bohn-Sarmiento, Salvador Saura-Grau, David Aguiar-Bujanda, Saray Galván-Ruíz, María Hernández-Sosa, Pedro Jiménez-Gallego, Marta Mori-De Santiago
Publikováno v:
Future Oncology. 10:1967-1980
ABSTRACT The prognosis of follicular lymphoma (FL) has significantly improved over the last decade, particularly following the introduction of the anti-CD20 monoclonal antibody rituximab, which has challenged the old concept of FL as an incurable dis
Autor:
José C. Rivero-Vera, Miguel Angel Limeres-gonzález, Samuel Hernández-Sarmiento, Marta Mori-De Santiago, María Jesús Blanco-Sánchez, Saray Galván-Ruíz, Ignacio Llorca-Mártinez, Salvador Saura Grau, José C. Cabrera-Marrero, María Hernández-Sosa, Pedro Jiménez-Gallego, Uriel Bohn-Sarmiento, David Aguiar-Bujanda
Publikováno v:
Hematological Oncology. 32:139-144
There is no standard treatment for patients with gastric marginal zone B-cell lymphoma of the mucosa-associated lymphoid tissue (MALT lymphoma) who are resistant to, or ineligible for, anti-Helicobacter pylori (anti-HP) therapy. In this study, we inv
Autor:
David, Aguiar-Bujanda, Ignacio, Llorca-Mártinez, José C, Rivero-Vera, María J, Blanco-Sánchez, Pedro, Jiménez-Gallego, Marta, Mori-De Santiago, Miguel A, Limeres-Gonzalez, José C, Cabrera-Marrero, María, Hernández-Sosa, Saray, Galván-Ruíz, Samuel, Hernández-Sarmiento, Salvador, Saura Grau, Uriel, Bohn-Sarmiento
Publikováno v:
Hematological oncology. 32(3)
There is no standard treatment for patients with gastric marginal zone B-cell lymphoma of the mucosa-associated lymphoid tissue (MALT lymphoma) who are resistant to, or ineligible for, anti-Helicobacter pylori (anti-HP) therapy. In this study, we inv
Autor:
María Jesús Blanco-Sánchez, Samuel Hernández-Sarmiento, David Aguiar-Bujanda, María Hernández-Sosa, Saray Galván-Ruíz
Publikováno v:
Cancer Management and Research
Cancer Management and Research, Vol 2015, Iss default, Pp 319-330 (2015)
Cancer Management and Research, Vol 2015, Iss default, Pp 319-330 (2015)
David Aguiar-Bujanda, María Jesús Blanco-Sánchez, María Hernández-Sosa, Saray Galván-Ruíz, Samuel Hernández-Sarmiento Department of Medical Oncology, Hospital Universitario de Gran Canaria Doctor Negrín, Las Palmas de Gran Canaria, Spain Abs